Parkinson-Related Dementias

Neurologic Clinics

Volumn 25, Issue 3, 2007, Pages 761-781

  Boeve, Bradley F ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERNEXIN; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID; ANTIOXIDANT; BACLOFEN; BOTULINUM TOXIN A; CHOLINESTERASE INHIBITOR; CLONAZEPAM; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; GALANTAMINE; HUNTINGTIN; LEVODOPA; PROPRANOLOL; RIVASTIGMINE; TAU PROTEIN;

ALZHEIMER DISEASE; ATTENTION; BRAIN ATROPHY; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOBASAL DEGENERATION; DAILY LIFE ACTIVITY; DEMENTIA; DEPTH PERCEPTION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; MENTAL CONCENTRATION; MUSCLE RIGIDITY; MYOCLONUS; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PARKINSON DISEASE; PHYSIOTHERAPY; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPEECH DISORDER; SPEECH THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR;

DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; PARKINSON DISEASE; PRACTICE GUIDELINES;

EID: 34447329558     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2007.04.002     Document Type: Review

References (62)

1. nd edition, volume 3 (2006), Informa Healthcare, Abingdon 3156-3206
2. Boeve B. Corticobasal degeneration. In: Adler C., and Ahlskog J. (Eds). Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician (2000), Human Press Inc., Totawa (NJ) 253-261
3. Boeve B., Lang A., and Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54 (2003) S15-S19
4. Boeve B. Corticobasal degeneration: the syndrome and the disease. In: Litvan I. (Ed). Atypical parkinsonian disorders (2005), Humana Press, Totawa (NJ) 309-334
5. Pillon B., Blin J., Vidailhet M., et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 45 (1995) 1477-1483
6. Massman P., Kreiter K., Jankovic J., et al. Neuropsychological functioning in cortical-basal ganglionic degeneration: differentiation from Alzheimer's disease. Neurology 46 (1996) 720-726
7. Josephs K.A., Tang-Wai D.F., Edland S.D., et al. Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol 61 12 (2004) 1881-1884
8. Dickson D., Bergeron C., Chin S., et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61 (2002) 935-946
9. Boeve B, Josephs K, Drubach D. Current and future management of the corticobasal syndrome and corticobasal degeneration. In: Litvan I, Duyckaerts C, editors. Handbook of clinical neurology: dementias. Scotland: Danderhall: Elsevier Press, Inc.; in press.
10. Kompoliti K., Goetz C., Boeve B., et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 55 (1998) 957-961
11. Wolf S., Winstein C., Miller J., et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA 296 (2006) 2095-2104
12. Litvan I., Agid Y., Calne D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47 (1996) 1-9
13. Litvan I., Mangone C.A., McKee A., et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 60 6 (1996) 615-620
14. Boeve B., Duffy J., Bartleson J., et al. Progressive nonfluent aphasic and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol 49 (2003) 72-78
15. Rippon G., Boeve B., Parisi J., et al. Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. Neurocase 11 (2005) 204-211
16. Josephs K., Boeve B., Duffy J., et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 11 (2005) 283-296
17. Dubois B., Pillon B., Legault F., et al. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol 45 (1988) 1194-1199
18. Pillon B., Deweer B., Michon A., et al. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases. Neurology 44 (1994) 1264-1270
19. Bak T., Crawford L., Hearn V., et al. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 11 (2005) 268-273
20. Adachi M., Kawanami T., Ohshima H., et al. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci 15 (2004) 125-132
21. Kato N., Arai K., and Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 210 (2003) 57-60
22. Josephs K.A., Whitwell J.L., Boeve B.F., et al. Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Ann Neurol 59 (2006) 200-203
23. Hauw J.-J., Daniel S., Dickson D., et al. Preliminary NINDS neuropathologic criteria for Steel-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44 (1994) 2015-2019
24. Nieforth K.A., and Golbe L.I. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16 4 (1993) 338-346
25. Cole D.G., and Growdon J.H. Therapy for progressive supranuclear palsy: past and future. J Neural Transm Suppl 42 (1994) 283-290
26. Kompoliti K., Goetz C.G., Litvan I., et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 55 8 (1998) 1099-1102
27. nd edition (2006), Informa Healthcare, Abingdon (VA) 3156-3206
28. Gilman S., Low P., Quinn N., et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163 (1999) 94-98
29. Konagaya M., Konagaya Y., Miwa S., et al. [Clinico-MRI study of hemispheric disorder in long-term follow-up cases of multiple system atrophy]. Rinsho Shinkeigaku 38 12 (1998) 1031-1036 [in Japanese]
30. Konagaya M., Sakai M., Matsuoka Y., et al. Multiple system atrophy with remarkable frontal lobe atrophy. Acta Neuropathologica 97 4 (1999) 423-428
31. Burk K., Daum I., and Rub U. Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord 21 (2006) 772-776
32. Boeve B., Silber M., Ferman T., et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16 (2001) 622-630
33. Boeve B., Silber M., Ferman T., et al. REM sleep behavior disorder in Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. In: Bedard M., Agid Y., and Chouinard S. (Eds). Mental and behavioral dysfunction in movement disorders (2003), Humana Press, Totowa (NJ) 383-397
34. Silber M., and Levine S. Stridor and death in multiple system atrophy. Mov Disord 15 (2000) 699-704
35. Dujardin K., Defebvre L., Krystkowiak P., et al. Executive function differences in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord 9 (2003) 205-211
36. Srivastava T., Singh S., Goyal V., et al. "Hot cross bun" sign in two patients with multiple system atrophy-cerebellar. Neurology 64 (2005) 128
37. Schrag A., Good C.D., Miszkiel K., et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54 3 (2000) 697-702
38. Gilman S. Functional imaging with positron emission tomography in multiple system atrophy. J Neural Transm 112 (2005) 1647-1655
39. Benarroch E.E., and Schmeichel A.M. Depletion of cholinergic mesopontine neurons in multiple system atrophy: a substrate for REM behavior disorder?. Neurology 58 (2002) A345
40. Benarroch E.E., Schmeichel A.M., Sandroni P., et al. Brainstem respiratory control: substrates of respiratory failure of multiple system atrophy. Acta Neuropathol (Berl) 113 1 (2007) 75-80 [Epub 2006 Nov 2007]
41. Hutton M., Lendon C.L., Rizzu P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998) 702-705
42. Baker M., Mackenzie I., Pickering-Brown S., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442 (2006) 916-919
43. Poorkaj P., Grossman M., Steinbart E., et al. Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol 58 (2001) 383-387
44. MICROTUBULE-ASSOCIATED PROTEIN TAU; MAPT. Avialable at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=157140; Accessed December 28, 2006.
45. Kertesz A. Pick's complex and FTDP-17. Mov Disord 18 (2003) S57-S62
46. Benussi L., Binetti G., Sina E., et al. A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol Aging (Dec 5, 2006) [Epub ahead of print]
47. Boeve B., Baker M., Dickson D., et al. Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain 129 (2006) 3103-3114
48. Cruts M., Gijselinck I., van der Zee J., et al. Null mutations in progranulin cause ubiquitin positive frontotemporal dementia linked to chromosome 17q21. Nature 442 (2006) 920-924
49. Gass J., Cannon A., Mackenzie I., et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 15 (2006) 2988-3001
50. Huey E.D., Grafman J., Wassermann E.M., et al. Characteristics of frontotemporal dementia patients with a Progranulin mutation. Ann Neurol 60 (2006) 374-380
51. Mackenzie I., Baker M., Pickering-Brown S., et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129 (2006) 3081-3090
52. Masellis M., Momeni P., Meschino W., et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 129 (2006) 3115-3123
53. Mukherjee O., Pastor P., Cairns N.J., et al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 60 (2006) 314-322
54. Pickering-Brown S., Baker M., Gass J., et al. Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain 129 (2006) 3124-3126
55. Snowden J., Pickering-Brown S., Mackenzie I., et al. Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain 129 (2006) 3091-3102
56. Boeve B., Tremont-Lukats I., Waclawik A., et al. Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain 128 (2005) 752-772
57. Pal P., Wszolek Z., Kishore A., et al. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). Parkinsonism Relat Disord 7 (2001) 81-88
58. Frank A., Wszolek Z., Jack C.R., et al. Distinctive MRI findings in pallido-ponto-nigral degeneration (PPND). Neurology 68 (2007) 620-621
59. Boeve B.F., Kelley B.J., Haidar W., et al. MRI findings in familial frontotemporal dementia and/or parkinsonism associated with mutations in progranulin. Neurology 68 Suppl 1 (2007) A388
60. Whitwell J.L., Jack Jr. C.R., Baker M., et al. Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch Neurol 64 (2007) 371-376
61. McKhann G.M., Albert M.S., Grossman M., et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58 11 (2001) 1803-1809
62. Neumann M., Sampathu D., Kwong L., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006) 130-133